147 related articles for article (PubMed ID: 11033338)
1. Structure and function of the dopamine transporter.
Chen N; Reith ME
Eur J Pharmacol; 2000 Sep; 405(1-3):329-39. PubMed ID: 11033338
[TBL] [Abstract][Full Text] [Related]
2. Binding domains for blockers and substrates on the cloned human dopamine transporter studied by protection against N-ethylmaleimide-induced reduction of 2 beta-carbomethoxy-3 beta-(4-fluorophenyl)[3H]tropane ([3H]WIN 35,428) binding.
Reith ME; Xu C; Coffey LL
Biochem Pharmacol; 1996 Nov; 52(9):1435-46. PubMed ID: 8937455
[TBL] [Abstract][Full Text] [Related]
3. Dopamine transporter: transmembrane phenylalanine mutations can selectively influence dopamine uptake and cocaine analog recognition.
Lin Z; Wang W; Kopajtic T; Revay RS; Uhl GR
Mol Pharmacol; 1999 Aug; 56(2):434-47. PubMed ID: 10419565
[TBL] [Abstract][Full Text] [Related]
4. Dopamine transporter tryptophan mutants highlight candidate dopamine- and cocaine-selective domains.
Lin Z; Wang W; Uhl GR
Mol Pharmacol; 2000 Dec; 58(6):1581-92. PubMed ID: 11093799
[TBL] [Abstract][Full Text] [Related]
5. Transport-dependent accessibility of a cytoplasmic loop cysteine in the human dopamine transporter.
Chen N; Ferrer JV; Javitch JA; Justice JB
J Biol Chem; 2000 Jan; 275(3):1608-14. PubMed ID: 10636852
[TBL] [Abstract][Full Text] [Related]
6. Evidence for distinct sodium-, dopamine-, and cocaine-dependent conformational changes in transmembrane segments 7 and 8 of the dopamine transporter.
Norregaard L; Loland CJ; Gether U
J Biol Chem; 2003 Aug; 278(33):30587-96. PubMed ID: 12773538
[TBL] [Abstract][Full Text] [Related]
7. Dopamine transporter proline mutations influence dopamine uptake, cocaine analog recognition, and expression.
Lin Z; Itokawa M; Uhl GR
FASEB J; 2000 Apr; 14(5):715-28. PubMed ID: 10744628
[TBL] [Abstract][Full Text] [Related]
8. Cocaine and GBR 12783 recognize nonidentical, overlapping binding domains on the dopamine neuronal carrier.
Saadouni S; Refahi-Lyamani F; Costentin J; Bonnet JJ
Eur J Pharmacol; 1994 Jul; 268(2):187-97. PubMed ID: 7957640
[TBL] [Abstract][Full Text] [Related]
9. Recognition of benztropine by the dopamine transporter (DAT) differs from that of the classical dopamine uptake inhibitors cocaine, methylphenidate, and mazindol as a function of a DAT transmembrane 1 aspartic acid residue.
Ukairo OT; Bondi CD; Newman AH; Kulkarni SS; Kozikowski AP; Pan S; Surratt CK
J Pharmacol Exp Ther; 2005 Aug; 314(2):575-83. PubMed ID: 15879005
[TBL] [Abstract][Full Text] [Related]
10. Cocaine alters the accessibility of endogenous cysteines in putative extracellular and intracellular loops of the human dopamine transporter.
Ferrer JV; Javitch JA
Proc Natl Acad Sci U S A; 1998 Aug; 95(16):9238-43. PubMed ID: 9689064
[TBL] [Abstract][Full Text] [Related]
11. Delineating structure-function relationships in the dopamine transporter from natural and engineered Zn2+ binding sites.
Gether U; Norregaard L; Loland CJ
Life Sci; 2001 Apr; 68(19-20):2187-98. PubMed ID: 11358327
[TBL] [Abstract][Full Text] [Related]
12. 3'-Chloro-3 alpha-(diphenylmethoxy)tropane but not 4'-chloro-3 alpha-(diphenylmethoxy)tropane produces a cocaine-like behavioral profile.
Kline RH; Izenwasser S; Katz JL; Joseph DB; Bowen WD; Newman AH
J Med Chem; 1997 Mar; 40(6):851-7. PubMed ID: 9083473
[TBL] [Abstract][Full Text] [Related]
13. Modeling of the pH dependence of the binding of WIN 35,428 to the dopamine transporter in rat striatal membranes: is the bioactive form positively charged or neutral?
Xu C; Reith ME
J Pharmacol Exp Ther; 1996 Sep; 278(3):1340-8. PubMed ID: 8819521
[TBL] [Abstract][Full Text] [Related]
14. Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding.
Kitayama S; Shimada S; Xu H; Markham L; Donovan DM; Uhl GR
Proc Natl Acad Sci U S A; 1992 Aug; 89(16):7782-5. PubMed ID: 1502198
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, dopamine transporter affinity, dopamine uptake inhibition, and locomotor stimulant activity of 2-substituted 3 beta-phenyltropane derivatives.
Xu L; Kelkar SV; Lomenzo SA; Izenwasser S; Katz JL; Kline RH; Trudell ML
J Med Chem; 1997 Mar; 40(6):858-63. PubMed ID: 9083474
[TBL] [Abstract][Full Text] [Related]
16. Differential effect of structural modification of human dopamine transporter on the inward and outward transport of dopamine.
Chen N; Justice JB
Brain Res Mol Brain Res; 2000 Feb; 75(2):208-15. PubMed ID: 10686341
[TBL] [Abstract][Full Text] [Related]
17. Dopamine transporter mutants, small molecules, and approaches to cocaine antagonist/dopamine transporter disinhibitor development.
Uhl G; Lin Z; Metzger T; Dar DE
Methods Enzymol; 1998; 296():456-65. PubMed ID: 9779467
[No Abstract] [Full Text] [Related]
18. Conformational changes in dopamine transporter intracellular regions upon cocaine binding and dopamine translocation.
Dehnes Y; Shan J; Beuming T; Shi L; Weinstein H; Javitch JA
Neurochem Int; 2014 Jul; 73():4-15. PubMed ID: 24576496
[TBL] [Abstract][Full Text] [Related]
19. Mutation of Trp84 and Asp313 of the dopamine transporter reveals similar mode of binding interaction for GBR12909 and benztropine as opposed to cocaine.
Chen N; Zhen J; Reith ME
J Neurochem; 2004 May; 89(4):853-64. PubMed ID: 15140185
[TBL] [Abstract][Full Text] [Related]
20. Delineation of an endogenous zinc-binding site in the human dopamine transporter.
Norregaard L; Frederiksen D; Nielsen EO; Gether U
EMBO J; 1998 Aug; 17(15):4266-73. PubMed ID: 9687495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
